Table of Contents
ISRN Oncology
Volume 2011 (2011), Article ID 405656, 7 pages
http://dx.doi.org/10.5402/2011/405656
Research Article

Cytotoxic Activity of Peripheral Blood Mononuclear Leukocytes, Activated by Interleukin-2/β-Cyclodextrin Nanocomposition against Androgen Receptor-Negative Prostate Cancers

1N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Kashirskoe Shosse, 24, Moscow 115478, Russia
2Chemical Diversity Research Institute, Rabochaya Street 2a, Khimki, Moscow 141401, Russia
3N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky Prospect 47, Moscow 119991, Russia
4Family Medicine Area, ASL1 Legnano and “Metabloc Cancer Center, ” c/o Centro Medico Kines, Castano Primo, 20022 Milan, Italy

Received 3 May 2011; Accepted 17 June 2011

Academic Editor: T.-C. Hour

Copyright © 2011 Natalia Yu. Anisimova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Nanocomposition comprised of interleukin-2 in suboptimal noneffective concentration and β-cyclodextrin was studied in vitro. This preparation as well as interleukin-2 in optimal concentration was shown to increase natural killer activity to K-562 cells and cytotoxicity of activated peripheral blood mononuclear cells (PBMCs) against PC-3 and DU 145 cells. At the same time β-cyclodextrin or interleukin-2 in equimolar concentrations did not influence the spontaneous killer activity of PBMC. This combination of cyclodextrin + interleukin-2 led to the decrease of interleukin-2 effective concentration by an order. This phenomenon could be explained by cyclodextrins ability to promote the formation of nanoparticles with drugs, which results in enhancing their water solubility and bioavailability. Besides, interleukine-2/β-cyclodextrin nanocomposition as opposed to interleukin-2 alone led to increasing the number of not only lymphocytes, but also macrophages contained in activated PBMC population. Application of low concentration of interleukin-2 allowing for good clinical efficiency may significantly mitigate the side effects of the drug and enable to develop adoption of immunotherapy for patients with androgen-resistant prostate cancer.